King’s College London Confidence in Concept
Lead Research Organisation:
King's College London
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- King's College London (Lead Research Organisation)
- Masaryk University (Collaboration)
- Charles River UK Limited (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- EP Solutions (Collaboration)
- Theragenetics Ltd (Collaboration)
- Centre for Genomic Regulation (CRG) (Collaboration)
- MicrofluidX (Collaboration)
- National Research Council (Collaboration)
- Women's Aid (Collaboration)
- University of Brescia (Collaboration)
- University College Hospital (Collaboration)
- Theragnostics Limited (Collaboration)
- Guy's and St Thomas' NHS Foundation Trust (Collaboration)
- University of Parma (Collaboration)
- Fluidigm (United States) (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications
Afaq A
(2019)
UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging.
in Nuclear medicine communications
Allert S
(2018)
Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers.
in mBio
Bartnicka JJ
(2020)
L-Cysteine-mediated modulation of copper trafficking in prostate cancer cells: an in vitro and in vivo investigation with 64Cu and 64Cu-PET.
in Metallomics : integrated biometal science
Bergholt MS
(2018)
Correlated Heterospectral Lipidomics for Biomolecular Profiling of Remyelination in Multiple Sclerosis.
in ACS central science
Bortolomeazzi M
(2020)
Immunogenomic profile of colorectal cancer response to immune checkpoint blockade
Bortolomeazzi M
(2020)
Identification of non-cancer cells from cancer transcriptomic data.
in Biochimica et biophysica acta. Gene regulatory mechanisms
Caprettini V
(2022)
Semiconducting Silicon Nanowires for Biomedical Applications
Chaix A
(2023)
Two-Photon Light Trigger siRNA Transfection of Cancer Cells Using Non-Toxic Porous Silicon Nanoparticles.
in Advanced healthcare materials
Chiappini C
(2018)
Handbook of Porous Silicon
| Title | COver figure for Advanced Materials |
| Description | We prepared an artistic cover image for the Gopal et al. publication on advanced materials, which was selected for cover display. |
| Type Of Art | Image |
| Year Produced | 2019 |
| Impact | Broader dissemination of our research through the community. |
| Description | BNMS PET-CT Commissioning Manifesto |
| Geographic Reach | National |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://cdn.ymaws.com/www.bnms.org.uk/resource/resmgr/guidelines/bnms_pet-ct_commissioning_ma.pdf |
| Description | BNMS UK PET standards |
| Geographic Reach | National |
| Policy Influence Type | Contribution to new or improved professional practice |
| Impact | Used by NHSE for next round of PET commissioning |
| URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718206/ |
| Description | A miniaturised laser isotope ratiometer for early diagnosis of sepsis by exhaled breath analysis |
| Amount | £73,601 (GBP) |
| Funding ID | ST/S000690/1 |
| Organisation | Science and Technologies Facilities Council (STFC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2020 |
| Description | Asthma UK Career Development Award |
| Amount | £250,000 (GBP) |
| Funding ID | AUK-CDA-2019-412 |
| Organisation | Asthma + Lung UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 10/2022 |
| Description | China Scholarship PhD studentship |
| Amount | £174,286 (GBP) |
| Organisation | Chinese Scholarship Council |
| Sector | Charity/Non Profit |
| Country | China |
| Start | 09/2023 |
| End | 09/2027 |
| Description | Correlated mass spectrometry and Raman spectroscopy for imaging of small molecules |
| Amount | £74,525 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 09/2020 |
| Description | Critical role for purinergic receptors in Candida albicans infection |
| Amount | £20,000 (GBP) |
| Funding ID | M680 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 09/2021 |
| Description | Delta Tissue |
| Amount | £4,218,568 (GBP) |
| Organisation | Wellcome LEAP |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2021 |
| End | 08/2023 |
| Description | Developing microfluidics bioreactor for CAR-T cell therapy |
| Amount | £120,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 09/2024 |
| Description | ERC Starting Grant |
| Amount | € 1,495,430 (EUR) |
| Funding ID | 759577 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 02/2018 |
| End | 01/2023 |
| Description | EU H2020 MSCA-ITN |
| Amount | € 3,000,000 (EUR) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2018 |
| End | 12/2022 |
| Description | Enhancing Periodontal Regeneration via Spatial and Temporal regulation of osteogenic signalling using Lithiated Porous Silicon Nanoparticles |
| Amount | £28,750 (GBP) |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 11/2021 |
| Description | Fungal peptide toxins in pathogenicity and immunity |
| Amount | £2,076,915 (GBP) |
| Funding ID | 214229/Z/18/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 04/2025 |
| Description | GENEPATTERN: A nanotextured platform for large-scale patterned gene delivery with single-cell resolution |
| Amount | £12,000 (GBP) |
| Organisation | The Royal Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2020 |
| Description | Health and Environmental Sciences Institute internal fund |
| Amount | £52,935 (GBP) |
| Organisation | Health and Environmental Sciences Institute (HESI) |
| Sector | Public |
| Country | United States |
| Start | 02/2018 |
| End | 01/2019 |
| Description | Imaging Radiation Resistance: Molecular And Imaging Biomarkers Of Radioresistance And Clinical Translation |
| Amount | £255,600 (GBP) |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2024 |
| End | 06/2029 |
| Description | Imaging avß3 integrin expression in skeletal metastases from breast cancer with 99mTc-maraciclatide SPECT |
| Amount | £192,546 (GBP) |
| Organisation | Breast Cancer Now |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2019 |
| Description | Imaging innovations to drive improved outcomes and health system efficiency: phase 2 |
| Amount | £3,464 (GBP) |
| Funding ID | STR140205B KCL. MAJ121002 |
| Organisation | Guy’s & St Thomas’ Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 06/2020 |
| Description | Imaging the Tumour Redox Microenvironment for Early Response Assessment in Cancer Patients |
| Amount | £192,352 (GBP) |
| Funding ID | PGL23/100049 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2024 |
| End | 06/2029 |
| Description | Improved Characterization Of Chronic Wounds In RDEB |
| Amount | £142,000 (GBP) |
| Organisation | DEBRA International |
| Sector | Charity/Non Profit |
| Country | Austria |
| Start | 05/2022 |
| End | 07/2025 |
| Description | Improved Characterization Of Chronic Wounds In RDEB |
| Amount | £140,175 (GBP) |
| Organisation | DEBRA International |
| Sector | Charity/Non Profit |
| Country | Austria |
| Start | 05/2022 |
| End | 05/2026 |
| Description | Improving the response of mental health services to domestic abuse perpetration(DAP) |
| Amount | £691,595 (GBP) |
| Funding ID | NIHR302243 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2026 |
| Description | Induced nutritional ketosis to improve FDG PET-CT scanning sensitivity in cancer |
| Amount | £73,840 (GBP) |
| Funding ID | MC_PC_17164 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 01/2020 |
| Description | Integrated multi-modal tissue state mapping of TNBC progression |
| Amount | £4,218,567 (GBP) |
| Organisation | Wellcome LEAP |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 08/2021 |
| End | 09/2024 |
| Description | Israeli Fellowship |
| Amount | £2,550 (GBP) |
| Organisation | British Council |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 02/2019 |
| Description | KCL Application for a Mental Health Data Pathfinder award |
| Amount | £1,497,000 (GBP) |
| Funding ID | MC_PC_17214 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 03/2021 |
| Description | KHP research fellowship |
| Amount | £25,000 (GBP) |
| Organisation | Kings Health Partners |
| Sector | Hospitals |
| Country | United Kingdom |
| Start | 04/2022 |
| End | 04/2023 |
| Description | KRI CoA: Lithiated porous silicon nanoparticles for alveolar bone regeneration in periodontal disease |
| Amount | £13,159 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 11/2021 |
| Description | Large dataset manipulation using OpenEP |
| Amount | £158,294 (GBP) |
| Funding ID | ARCHER2-eCSE08-1 |
| Organisation | ARCHER |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2023 |
| End | 11/2024 |
| Description | Microfluidics-based bioprocessing platform for high-throughput cell and gene therapy manufacturing applications |
| Amount | £139,557 (GBP) |
| Organisation | MedCity |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 06/2021 |
| Description | Montelukast actions in the brain; potential therapy for perinatal brain injury |
| Amount | £30,000 (GBP) |
| Funding ID | M833 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2021 |
| Description | NanoCol: A nanoneedle bandage for topical intracellular COL7A1 gene therapy to accelerate wound healing in recessive dystrophic epidermolysis bullosa |
| Amount | £320,110 (GBP) |
| Organisation | Sohana Research Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2022 |
| Description | Nanokicking Nanoneedles for CRISPR/Cas9-based gene editing in epidermolysis bullosa |
| Amount | £49,996 (GBP) |
| Organisation | King's College London |
| Department | London Advanced Therapies |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2021 |
| End | 04/2022 |
| Description | National Cancer Imaging Translational Accelerator |
| Amount | £5,000,000 (GBP) |
| Funding ID | C1519/A28682 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 03/2023 |
| Description | National Total Body PET Centre |
| Amount | £11,986,625 (GBP) |
| Funding ID | MR/Y008987/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2023 |
| End | 09/2030 |
| Description | New Capability for Spatial Molecular Imaging at King's College London |
| Amount | £262,760 (GBP) |
| Funding ID | MR/X012476/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 03/2023 |
| Description | Next generation molecular imaging and therapy with radionuclides |
| Amount | £6,437,105 (GBP) |
| Funding ID | EP/S032789/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2024 |
| Description | PROSPER Study |
| Amount | £60,000 (GBP) |
| Organisation | Theragnostics Limited |
| Sector | Private |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2020 |
| Description | PhD Studentship |
| Amount | £69,888 (GBP) |
| Funding ID | A1501 |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Prenatal ThERapy for SIckle CelL DisEaSe (PERICLES) |
| Amount | £233,788 (GBP) |
| Organisation | Fetal Medicine Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 11/2027 |
| Description | Project Grant |
| Amount | £192,952 (GBP) |
| Funding ID | NC/R001006/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Shedding light on platinum chemotherapy: a new mechanistic approach |
| Amount | £250,000 (GBP) |
| Funding ID | 209173/Z/17/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 06/2023 |
| Description | Using Electronic Health Registers Phenotyping For The Automatic Detection of Individuals At Risk and Prediction of Psychosis |
| Amount | £31,521 (GBP) |
| Funding ID | RE14597 |
| Organisation | H. Lundbeck A/S |
| Sector | Private |
| Country | Denmark |
| Start | 08/2018 |
| End | 09/2019 |
| Description | Victimization and domestic violence experienced by mental health services users during the COVID-19 lockdown period: understanding outcomes and their correlates. |
| Amount | £24,873 (GBP) |
| Organisation | United Kingdom Research and Innovation |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2021 |
| End | 09/2022 |
| Description | Violence, Abuse and Mental Health: Opportunities for Change |
| Amount | £1,020,181 (GBP) |
| Funding ID | ES/S004424/1 |
| Organisation | Economic and Social Research Council |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 10/2023 |
| Description | Wound care and its complications in patients with Epidermolysis Bullosa |
| Amount | £112,499 (GBP) |
| Organisation | DEBRA International |
| Sector | Charity/Non Profit |
| Country | Austria |
| Start | 03/2021 |
| End | 03/2024 |
| Title | Natural Language Processing (NLP) application to identify instances of violence and abuse in electronic health records from secondary mental health care |
| Description | The South London and Maudsley NHS Foundation Trust (SLaM) is the largest provider of secondary mental healthcare in Europe, serving a population of approximately 1.2 million people. Fully electronic health records (EHRs) were implemented in SLaM during 2006. Between 2007 and 2008, the Clinical Record Interactive Search (CRIS) application was developed to generate a psuedonymised version of SLaM's EHRs for use as a live-updated research database; CRIS data has since been extended through the development of NLP applications. The current project therefore sought to develop an NLP tool to identify instances of violence and abuse. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2018 |
| Provided To Others? | Yes |
| Impact | One manuscript is in preparation describing the development process of the NLP application, and another is planned to break down the results of the NLP work in further detail. |
| Title | Training files for THP-PSMA PET/CT |
| Description | Developed set of training cases in preparation for training investigators for a phase 3 study. Each scan read by 2 experts and consensus obtained. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | Abstract at BNMS 2020 Inter-reader reliability of 68Ga-THP-PSMA PET/CT interpretation in patients with prostate cancer |
| Description | CAPTAIN15: a first in man study evaluating the safety, tolerability and efficacy of intratumourally injected Interleukin-15 in men with prostate cancer |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Study in preparation that will utilise PSMA PET/MRI as an imaging biomarker. |
| Collaborator Contribution | Leading the project |
| Impact | Grant awarded: CAncer Of The Prostate -IntraTumoural Administration Of INterleukin-15 (CAPTAIN-15) - A First-in Man Phase 1 Safety And Efficacy Trial In Prostate Cancer Patients Funder: Lotto LR S.R.L Collaborative project - lead institution: King's College London Total value of award to all partners: £750,000 Value of award to King´s: £354,939 Date: 1/11/2022 ? 31/10/2024 |
| Start Year | 2020 |
| Description | Candidalysin molecular dynamics |
| Organisation | Masaryk University |
| Country | Czech Republic |
| Sector | Academic/University |
| PI Contribution | We provide the Candidalysin sequence |
| Collaborator Contribution | Determine Candidalysin structure via molecular dynamic simulations |
| Impact | Currently onging |
| Start Year | 2017 |
| Description | Charles River Labs - validation of SPAR on respiratory data |
| Organisation | Charles River UK Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Analysis of respiratory waveform data from different models/drug treatments assessing respiratory function. |
| Collaborator Contribution | Provision of GLP respiratory plethysmography data in a model of lung fibrosis. |
| Impact | Project grant application currently under review at NC3R. Multidisciplinary -pharmacology, physiology and mathematics. |
| Start Year | 2018 |
| Description | Collaboration with Andrew Beavil and Sophia Karagiannis |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We defined the concept and grant application |
| Collaborator Contribution | Provoded expertise on antibody cloning |
| Impact | No outputs as yet as collaboration only commenced in February 2018 |
| Start Year | 2018 |
| Description | Collaboration with Jo Spencer (KCL), Susanne Heck (GSTT-BRC), Fuidigm |
| Organisation | Fluidigm Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Validated IHC antibodies on appendix and colorectal cancer samples to be tagged for use on Hyperion |
| Collaborator Contribution | Fluidigm provided a panel of tagged antibodies to test on appendix; Susanne Heck and her team at the BRC mass cytometry facilities provided expertise for tritration and tagging; Jo Spencer is co-I on the grant and is the expert on gastrointenstinal immunology |
| Impact | The collaboration is highly disciplinary and involves mucosal immunology (Jo Spencer); Time of Flight Mass Cytometry (CyTOF; Susanne Heck, Fluidigm); Genomics and data analysis (Francesca Ciccarelli) |
| Start Year | 2018 |
| Description | Dr G Azad radiotherapy collaboration |
| Organisation | Guy's and St Thomas' NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | We have made HRA approved amendments to allow additional radiotherapy planning related endpoints to the trial. This has required additional technical input from the local physics and radiographer team to optimise the MRI sequences. |
| Collaborator Contribution | Dr Azad (consultant radiotherapist) has joined the study to recruit and explore potential radiotherapy planning feasibility and objectives from the hybrid imaging information. |
| Impact | HRA / REC amendment approved Recruitment recommenced 2/23: (3 additional patients recruited to date) |
| Start Year | 2022 |
| Description | Engineering extracellular vesicles |
| Organisation | University of Brescia |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | We developed an approach to engineer the payload of extracellular vesicles by generating topgraphical substrates that stimulate endocytosis and regulate exocytosis of nanoparticle payloads. |
| Collaborator Contribution | The group of Professor Bergese in Italy has a strong expertise in the characterisation of extracellular vesicles and is providing protocols, expertise and instrumentation for characterisation of the engineered vescicles. |
| Impact | Collaboration just started |
| Start Year | 2019 |
| Description | Fungal peptide toxins |
| Organisation | Centre for Genomic Regulation (CRG) |
| Country | Spain |
| Sector | Academic/University |
| PI Contribution | We provide the Candidalysin sequence |
| Collaborator Contribution | Undertake computational analysis to identify similar fungal peptide toxins |
| Impact | Identified approx 2,000 possible toxins |
| Start Year | 2016 |
| Description | GENEPATTERN: A nanotextured platform for large-scale patterned gene delivery with single-cell resolution |
| Organisation | National Research Council |
| Country | Italy |
| Sector | Public |
| PI Contribution | We engineered nanotextured substrates that stimulate cellular uptake to mediate the patterned delivery of payloads by patterning the payload themselves on the substrates. |
| Collaborator Contribution | The group of Dr DeStefano at CNR Napoli has expertise in patterned polymeric coatings for the controlled release of payloads. They developed a PEG coating strategy for the sustained release of the DNA loaded within the nanotextured substrates. |
| Impact | Oral presentations of the progress from this work by Dr Valeria Caprettini from the Chiappini group at BSNM 2019, PSST 2020 and WBC 2020. |
| Start Year | 2018 |
| Description | Local drug delivery for cornea endothelium |
| Organisation | University of Parma |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | We demonstrated that nanoneedles can directly deliver nucleic acids to the endothelium of the cornea, which we are now planning to use for therapeutic purposes. |
| Collaborator Contribution | The partner provided expertise in cornea disease, the cell biology expertise and the access to clinical samples. |
| Impact | The collaboration has recently been established. We have determined the feasibility of the approach and move forward to translating it. The collaboration is multidisciplinary, it involves our expertise in biomaterials and drug delivery with the partners expertise in medical practice, regenerative medicine and cell/molecular biology. |
| Start Year | 2017 |
| Description | Microfluidic Bioprocessing Platform for T-Cells in Cell and Gene therapy |
| Organisation | MicrofluidX |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Providing expertise for testing cell expansion in microfluidic platform for CAR-T applications. |
| Collaborator Contribution | MicrofluidX developed an innovative platform for the bioprocessing of CAR-T cells in clinical applications. We are collaborating to test the performance of this system. |
| Impact | just started |
| Start Year | 2020 |
| Description | Non-Invasive Atrial Fibrillation Substrate Assessment Using Exercise-Electrocardiographic Imaging |
| Organisation | EP Solutions |
| Country | Switzerland |
| Sector | Private |
| PI Contribution | NA |
| Collaborator Contribution | Provide the ECGI imaging system, technical support and some consumables |
| Impact | NA |
| Start Year | 2017 |
| Description | Phase II trial of 68Ga-THP-PSMA PET/CT |
| Organisation | University College Hospital |
| Department | University College London Hospitals Charity (UCLH) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Co-investigator, recruited participants and helped analyse data |
| Collaborator Contribution | Two centre clinical trial between UCLH and KCL/GSTT |
| Impact | Study complete. Manuscript published. Afaq, A., Payne, H., Davda, R., Hines, J., Cook, G. J. R., Meagher, M., Priftakis, D., Warbey, V. S., Kelkar, A., Orczyk, C., Mitra, A., Needleman, S., Ferris, M., Mullen, G., & Bomanji, J. (2021). A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 62(12), 1727-1734. Advance online publication. https://doi.org/10.2967/jnumed.120.257527 |
| Start Year | 2019 |
| Description | The transcriptome of bone marrow and nasal polyp plasma cells. |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I provided the RNA isolated from various bone marrow and nasal polyp cell population for microarray analysis |
| Collaborator Contribution | David Chambers generated cDNA, labeled the the cDNA and hybridised onto a human genome U133 plus 2.0 array. |
| Impact | None to report yet |
| Start Year | 2018 |
| Description | Theragnostics Ltd (PROSPER Study) |
| Organisation | Theragenetics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | PI and research fellow running the trial |
| Collaborator Contribution | Theragnostics Ltd have provided tracer FoC and have part funded a research fellow |
| Impact | PROSPER Study in setup awaiting final R&D approval |
| Start Year | 2018 |
| Description | Theragnostics Ltd collaboration in THP-PSMA PET imaging |
| Organisation | Theragnostics Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | PI and PhD student leading research |
| Collaborator Contribution | Theragnostics have provided research funding and tracer kits |
| Impact | Publications Training case file Kulkarni, M., Hughes, S., Mallia, A., Gibson, V., Young, J., Aggarwal, A., Morris, S., Challacombe, B., Popert, R., Brown, C., Cathcart, P., Dasgupta, P., Warbey, V. S., & Cook, G. J. R. (2020). The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. European journal of nuclear medicine and molecular imaging, 47(3), 674-686. https://doi.org/10.1007/s00259-019-04643-7 |
| Start Year | 2018 |
| Description | UKRI Grant on Victimization and domestic violence experienced by mental health services users during the COVID-19 lockdown period: understanding outcomes and their correlates |
| Organisation | Women's Aid |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | This grant builds on the development work funded by the NIHR Research Professorship to develop a natural language processing application to identify domestic abuse in electronic health records. We are now planning to use this NLP app to examine the impact of Covid-19. This is therefore a collaboration between the NIHR BRC informatics team and Women's Aid and myself. |
| Collaborator Contribution | Women's Aid are helping with development of the protocol and dissemination of results. |
| Impact | N/A |
| Start Year | 2020 |
| Description | University of Nottingham - Cardiotoxicity screening platform |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have been analysing cardiomyocyte data under different drug treatment regimens and have revealed altered characteristics in the shape of the contractility waveform which may increase the sensitivity of detecting cardiotoxic effects of new drugs in development. |
| Collaborator Contribution | Provision of cardiomyocyte data |
| Impact | Data is being collected for grant application. We have also discussed the data with the Health and Environmental Sciences Institute who partner with industry tobring technological advancements to drug efficacy and safety screening. |
| Start Year | 2019 |
| Title | LARA manual for mental health professionals |
| Description | This manual was developed in a stakeholder workshop and built on our previous work on domestic violence and abuse experienced by mental health service users. |
| IP Reference | |
| Protection | Trade Mark |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Resource downloaded for use by NHS Mental Health Trusts and available on RCN WEBSITE |
| Title | LITHIATED SILICON |
| Description | Lithiated porous silicon particles comprising lithium, silicon and oxygen, a method of making the particles, and uses of the particles are described. |
| IP Reference | WO2022029277 |
| Protection | Patent application published |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | In discussion for licesning to Geistlich AG for the treatment of periodontal disease |
| Title | NANOPROJECTION ARRAY AND A METHOD FOR FABRICATING A NANOPROJECTION ARRAY |
| Description | The present disclosure relates to a method for fabricating an array of nanoprojections, where the nanoprojections may include nanopillars, nanowires, nanoneedles or nanocones. The present disclosure also relates to an array of the nanoprojections, and to uses of such arrays. |
| IP Reference | WO2023180748 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | Further funding secured from Fight for Sight for the development of ocular therapies. |
| Title | PEPTIDES AND BINDING PARTNERS THEREFOR |
| Description | The invention provides a peptide obtainable from C. albicansas well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity. |
| IP Reference | WO2014167335 |
| Protection | Patent granted |
| Year Protection Granted | 2014 |
| Licensed | No |
| Impact | US Patent No.: 9,969,796, EU patent No: 984103. Applications pending in China (CN 201480033206.2) and USA (US 15/933,660) |
| Title | Galliprost (68Ga-TH-PSMA) |
| Description | Phase 2 trial complete. Phase 3 trial in preparation. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2019 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Publications |
| URL | https://clinicaltrials.gov/show/NCT03617588 |
| Title | Galliprost (68Ga-THP-PSMA) |
| Description | Evaluation of Prostate-Specific Membrane Antigen (68Ga) PET/CT as a tool to guide treatment choice in patients with high risk prostate cancer in progress |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Refinement. Clinical |
| Year Development Stage Completed | 2020 |
| Development Status | Closed |
| Clinical Trial? | Yes |
| Impact | Publications. Galliprost is in clinical use in several UK departments. A phase 2 trial is completed. A training case file has been formed for training for a phase 3 study. |
| Title | Electronic automatic screening tool to detect individuals at risk of psychosis in secondary mental health care |
| Description | An automatic risk calculator which is embedded with Electronic Health Records to screen large NHS databases and detect individuals who might be at risk of developing psychosis |
| Type Of Technology | Detection Devices |
| Year Produced | 2019 |
| Impact | -The detection tool has attracteed industrial interest and a specific industry funded grant -The tool has been endorsed by a national (NIHR MH TRC EP Workstream) and international (ECNP TWG PMD-MHP) infrastructures -The tool is being used to support ongoing large-scale grant applications (EUNIA) |
| URL | http://psychosis-risk.net/ |
| Title | Gazele: Microscale Brain Network Dynamics |
| Description | Software package for the complete study, data manipulation and modelling of the dynamics and structure of complex brain networks. It requires zero knowledge of programming or scripting and consists of two standalone applications, Gazele and Coconi. |
| Type Of Technology | Webtool/Application |
| Year Produced | 2019 |
| Impact | None yet as still undergoing release. |
| Title | SPARKS app |
| Description | SPARKS is a graphic user interface that embeds the symmetric project attractor reconstruction method combining with visual outputs, scalar metrics and in build statistical analysis developed by a PhD student funded by DRIVE health CDT at KCL (PI Nandi). It is being made available to academic and clinical collaborators for use to independently evaluate the technology on their existing datasets and minimises the need to organise data access agreements. |
| Type Of Technology | New/Improved Technique/Technology |
| Year Produced | 2021 |
| Impact | Currently being tested: University of Nottingham - in vivo drug safety screening GSTT - fetal ECGs Royal Brompton hospital - paediatric ICU data KCH - healthy human volunteer and patient data (respiratory) |
| Title | sysSVM |
| Description | Identification of cancer driver genes based on machine learning |
| Type Of Technology | Software |
| Year Produced | 2018 |
| Impact | We succeeded to identify cancer driver genes in each single OAC patient from the OCCAMS cohort |
| Company Name | Piramidal Ltd |
| Description | |
| Year Established | 2017 |
| Impact | NA |
| Description | A formal workshop with Healthy London Partnership and NHS England |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | A one-day workshop with NHS England and Healthy London Partnership to promote innovative models of care for young people with emerging mental disorders. The workshop is shaping the national strategy to implement the NHS Long Term Plans for early detection and treatment of mental disorders. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.healthylondon.org |
| Description | Asthma UK Centre in Allergic Mechanisms of Asthma Science day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | I gave a talk at the science day of Asthma UK Centre in Allergic Mechanisms of Asthma. The science day was organised by Imperial college and King's College London at St Mary's Campus, Imperial College. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Asthma UK Magazine Interview |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | I gave an interview to the Asthma UK Magazine in relation to my research project that is being funded by the Asthma UK Career Development Award. Asthma UK Magazine is a quarterly printed magazine. |
| Year(s) Of Engagement Activity | 2020 |
| Description | BioDynamics 2018: Dynamic network characterisation of icEEG interictal spike events in TLE patients may associate with surgical outcome (DS) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Purpose Microstructural EEG elements and their functional networks relate to many neurophysiological functions of the brain and may reveal abnormalities. The Interictal Epileptiform Discharge (IED), a hallmark graphoelement of epileptic EEG, is thought to play a key role in the formation and evolution of pathogenic networks in epilepsy. Although IEDs have previously been studied, their network attributes are still to be fully elucidated. Here, we perform a dynamic network characterisation of IEDs with high temporal selectivity, regarding this as a readily available window into the epileptic brain state. Methods Commonly, brain connectivity studies of epilepsy using EEG analyse either entire recordings, including pathogenic but also normal brain activities, or lengthy rare events, such as epileptic seizures. For the first time here, we estimate pathogenic networks that characterise very brief IEDs lasting a few 10's of milliseconds, alone. We use an inverse power method for estimation of sparse principal component analysis in order to reveal connectivity properties that are consistent across subjects. Finally, we employ centrality measures (eg. betweenness, eigencentrality, closeness) to identify areas that are either influential or play an important role in the IED network function. Results In a preliminary analysis of four exemplar patients, we examined their first EEG at initial epilepsy onset; subsequently, two proved to be treatment-responsive and two were treatment-resistant. We show a difference in their network features. Specifically, IED networks differ in their modularity. Conclusion We conclude that network investigation of IEDs may reveal predictive biomarkers for early identification of treatment outcome. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Bioindustry Association Webinar: AI solutions for earlier disease detection |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invitation to give a webinar as part of International Women's Day for the Bioindustry Association. This gave me the opportunity to present the work to a wider audience within the Bioindustry sector. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.youtube.com/watch?v=c4VJGlFDN-8 |
| Description | Biological Surfaces and Interfaces FEBS workshop |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Around 160 international leading experts interested in biological surfaces gathered to discuss the latest development on the subject. I was selected among few early career researcher to give an oral presentation on my research followed by Q&A. This raised the awareness and interest of my work and future engagements with the conference organization. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://mimeresearch.com/biointerfaces2017/ |
| Description | British Association of Urological Surgeons |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | British Association of Urological Surgeons Lecture on state-of-the-art PET imaging in prostate cancer and update on PROSPER Study |
| Year(s) Of Engagement Activity | 2018 |
| Description | British Nuclear Medicine PET tracer manifesto |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | publication of a national radiopharmaceutical manifesto |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cdn.ymaws.com/www.bnms.org.uk/resource/resmgr/guidelines/bnms_pet-ct_commissioning_ma.pdf |
| Description | British Society of Allergy and Clinical Immunology Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The organising commute of the BSACI 2019 conference invited me to give a talk at the 2019 conference held in Harrogate, UK. My talk was in the session called "What is new in IgE?". The invitation to give a talk at the conference was made to replace another speaker that had to pull out of the conference. This was after the final program was printed. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://bsacimeeting.org |
| Description | COVID-19 the vaccination strategy |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented the strategy to discorver, manufacture and deliver vaccines to lawyers interested in evaluating the legal implications of mandatory vs. voluntary vaccination approaches. |
| Year(s) Of Engagement Activity | 2021 |
| Description | Computational Biomarkers in Early Identification and Prediction of Intractable Epilepsy (DS) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Purpose Microstructural EEG elements and their functional networks relate to many neurophysiological functions of the brain and may reveal abnormalities. The Interictal Epileptiform Discharge (IED), a hallmark graphoelement of epileptic EEG, is thought to play a key role in the formation and evolution of pathogenic networks in epilepsy. Although IEDs have previously been studied, their network attributes are still to be fully elucidated. Here, we perform a dynamic network characterisation of IEDs with high temporal selectivity, regarding this as a readily available window into the epileptic brain state. Methods Commonly, brain connectivity studies of epilepsy using EEG analyse either entire recordings, including pathogenic but also normal brain activities, or lengthy rare events, such as epileptic seizures. For the first time here, we estimate pathogenic networks that characterise very brief IEDs lasting a few 10's of milliseconds, alone. We use an inverse power method for estimation of sparse principal component analysis in order to reveal connectivity properties that are consistent across subjects. Finally, we employ centrality measures (eg. betweenness, eigencentrality, closeness) to identify areas that are either influential or play an important role in the IED network function. Results In a preliminary analysis of four exemplar patients, we examined their first EEG at initial epilepsy onset; subsequently, two proved to be treatment-responsive and two were treatment-resistant. We show a difference in their network features. Specifically, IED networks differ in their modularity. Conclusion We conclude that network investigation of IEDs may reveal predictive biomarkers for early identification of treatment outcome. |
| Year(s) Of Engagement Activity | 2018 |
| Description | CureEB Family Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Talks and discussion during the CureEB 2023 family day. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Eureka Blog for Charles River Labs: 'Big Data is all around us, but we're not using it...' |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | This science blog was written as part of the Eureka Series by Charles River Labs - an international CRO leading in medicines efficacy and safety assessment. This showcased a pilot project that we undertook with the company. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://eureka.criver.com/big-data-is-all-around-us-but-were-not-using-it/ |
| Description | Europhysiology 2018: Lunchtime lecture: Maths in medicine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited lunchtime lecture at Europhysiology 2018 -international physiology conference. This led to a number of research questions and publicised the method to a wider audience. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://static.physoc.org/app/uploads/2019/03/22193716/Europhysiology-2018-PROG-ONLINE.pdf |
| Description | Featured Scientist: ADInstruments Science Heroes |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | I was featured as part of the 'Science Heroes' campaign by ADInstruments - showcasing physiology research to a wider audience. This video has been shared widely and has been a useful way to publicise the method to support research collaboration and commercialization discussions. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.adinstruments.com/manasi-nandi |
| Description | Fungal infections - Poland Press |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview with local journalist and article published in local Press |
| Year(s) Of Engagement Activity | 2018 |
| Description | Heads Up |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | The Faculty organised a showcase of artistic collaborations leading to performances and work of art. Our group exhibited artwork generated from our research. The exhibit was open for 1 month in the Gallery at Bush House, and was visited by the general public, students and staff from King's. |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited talk: Addenbrookes Hospital and Cambridge University Cardiovascular Centre |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Clinicians and academic researchers attended this lecture. As a result, i have established a number of ongoing collaborations. In particular, links with Addenbrookes hospital from where we will be able to access patient data for proof of concept studies about the utility of the mathematical method. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Keynote presentation: British Heart Foundation/NC3R Cardiovascular Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote presentation at BHF/NC3R showcase describing our mathematical method and application to the earlier detection of disease or drug effects. This talk led to new collaborations from both academic and industry labs which are ongoing. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://nc3rs.org.uk/events/nc3rs-cardiovascular-showcase-event |
| Description | Keynote: Dx Toxicology: Strategies for Success in Discovery and Development |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote lecture describing our research and its applications to drug discovery. This led to a number of questions and valuable feedback. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.apconix.com/symposium-dx-toxicology-strategies-for-success-in-discovery-and-development/ |
| Description | Keynote: Eurotoxicology meeting 2018: Health and Environmental Sciences Institute CITE lecturer |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Nominated as the HESI-CITE (Combining Interdisciplinary and Translational Expertise) lecturer. Audience consisted primarily of industry and academic scientists working in the field of drug safety assessment. This led to a number of questions and new industry collaborations and interaction with key opinion leaders in this field. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.eurotox-congress.com/2018/?s=detailed-programmeClone |
| Description | LARA-VP workshop (Addressing domestic violence in mental health services) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | We held a workshop on the information mental health practitioners need in order to respond to domestic violence victimisation and perpetration safely. A draft contents of a potential manual for mental health services was provided for the participants to comment on and presentations were given on current evidence base. The workshop was attended by safeguarding nurses, directors of nursing, chief executives of domestic violence charities, senior practitioners at number of different mental health trusts, policymakers at the Department of Health and Social Care, academics and mental health service users. There was agreement that an up-to-date valuable would be helpful for mental health trusts and the lead for domestic violence at the Department of Health and Social Care agreed to disseminated to all mental health trusts. NHS Improvement and the CQC have also expressed interest and details of the manual have been widely disseminated within our own organisation e.g. King's Health Partners newsletter, NHS England, CQC, DHSC etc. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.kcl.ac.uk/ioppn/depts/hspr/research/ceph/wmh/lara-vp-download-form |
| Description | Meeting with NHS England (Heather Caudle, Director of Nursing for Improvement) to discuss LARA-VP intervention |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | This meeting was set-up in order for Louise Howard and Emma Yapp to explain the LARA intervention, both in terms of the pilot intervention and current progress, to Heather Caudle, Director of Nursing for Improvement at NHS England. Heather Caudle expressed concern about overall lack of identification of domestic violence within mental health services, and about the failure of nurses in both primary and secondary care to assist in this practice. LH stressed the importance of working with the domestic violence sector in delivering interventions, and summarised the LARA pilot, leading to further discussion of improved the response to domestic violence within nursing. Louise Howard and Emma Yapp to attend next meeting of Strategic Leads recently set up across the Home Office, DoH and the NHS. |
| Year(s) Of Engagement Activity | 2018 |
| Description | MyCoL |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | The aim is to enable the fungal community (e.g. researchers, academics, clinicians, podiatrists, etc) in London to get together on a regular basis to discuss their work and exchange ideas, in order to facilitate research collaborations, apply for funding, promote student exchanges and undertake public engagement activities. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://www.eventbrite.co.uk/e/mycol-mycology-community-of-london-second-meeting-tickets-97717645107... |
| Description | National standard for PET/CT |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Publications of expected standards for PET/CT in UK |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718206/ |
| Description | New collaboration opportunities to meet the 21st Century challenge of developing accurate asthma diagnostic tools |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | This informal workshop aimed to discuss the opportunities and barriers of identifying and developing new biomarkers for asthma diagnostic tests and determine the next steps required in addressing the defined challenges through collaboration. The development of new diagnostics is embedded within the fifteen Key Research Priorities, as identified by the European Asthma Research and Innovation Partnership (EARIP). Challenges 1. Developing low-cost diagnosis devices that can provide rapid proteomic and metabolomic analysis of serum, EBC and urine 2. Further research into assessing VOCs using electrosensor (eNose) to phenotype asthma and predict asthma attacks Discussion • It was decided early in the discussion to focus solely on Challenge 1, as researchers should be looking at a broad range of metabolites in all matrices at this stage in the search for a gold standard diagnostic test. • The group noted that many drugs currently available failed their initial tests because patients enrolled in trials weren't stratified. They agreed that the development of new diagnostics will necessarily come from a personalised medicine approach. Next steps • There is a need to tackle conflicting guidance on how to diagnose asthma (whether it is physiology-based or symptom-based). Asthma UK are responding to the new NICE guidelines. • Researchers should develop a consensus paper detailing the current diagnostic landscape in terms of the available technology and biomarkers. From that, a working group would be better informed to define the needs and challenges ahead more precisely and crucially determine what information they wish to obtain from a diagnostic test. • Researchers should aim to identify three or four biomarkers from any matrix. An ideal biomarker should sit within the mechanistic pathway and be associated with the disease symptoms. It should be able to phenotype patients and will itself be altered by the treatment so that response is measurable. • Researchers require better access to biobanks and existing patient datasets and these barriers should be tackled. Simon Young at Astra Zeneca UK stated that they have access to cohort data and invited researchers to approach them for access. • When trials are designed, they must include multiple measures from the same patients over a long time period to understand variation in biomarkers. • GPs require better implementation of existing biomarkers and clinical risk prediction tools, and it was recommended that they explore the possibility of utilising/developing diagnostic hubs to overcome this. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.asthma.org.uk/globalassets/get-involved/external-affairs-campaigns/asthma-needs-research... |
| Description | Patient group workshop " Discover Science through Art" |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | This activity was to relate our MRC funded research to patients through art. After describing our work and hosting a lab visit the patients were taught to express their understanding of the research in art. The designs they achieved were then printed into scarves that each patients could keep. The patients really enjoyed the workshop and the interaction with the scientist. To quote one patient " I just wanted to reiterate how much I enjoyed Tuesday's workshop, I absolutely believe that it's such a great thg for both patients and researchers to have more interaction with each other" Moreover this workshop really allowed patients to understand our research as exemplified by the quote 'Cells are so influenced by the environment, aren't they?' We had planned to continue these workshops into 2020 but the Covid-19 pandemic inhibited this. As an alternative we are in the process of developing a whiteboard video describing our research that will be loaded onto YouTube. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://twitter.com/SweetBiology |
| Description | Public engagement - Soapbox Science, Brighton 2018 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Soapbox science in a national public outreach platform for promoting women scientists and their work. I co-presented our mathematical method and its application to health care with the post doc who was employed by the KHP R&D challenge fund (MRC confidence in concept award). This took place on a soapbox on Brighton beach and members of the public were able to gather and listen to the different speakers. Questions spanned from the value of big data in healthcare to how our work may help patients in critical care. Through this exhibition, i was contacted by a lead for STEM girls club and have since participated in a number of school events around STEM including a career workshop about STEM subjects and a further schools talk about the work we do. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://soapboxscience.org/soapbox-science-2018-brighton/ |
| Description | Talk to a Commercial Company, Palleon |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | This was a talk to Palleon Pharmaceuticals to describe our recent paper published in Communications Biology. This company's focus is on the Glyco-immune checkpoint and they are developing agents to prevent siglec-ligand binding. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://palleonpharma.com |
| Description | Tissue web site entry |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was describing our use of tissue from the Tissue Directory and Coordination Centre. |
| Year(s) Of Engagement Activity | 2020 |
| URL | https://biobankinguk.org/advancing-our-understanding-of-breast-cancer/ |
| Description | Visit of CRUK donors |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Visit by donors to CRUK. Our MRC funded research was describe by myself and the members of the lab showed the participants some simple experiments. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Workshop on CyTOF |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | Together with Jo Spencer and Susanne Heck we organised a workshop on solid cyTOF to introduce the technique and its potentials to the broader audience of research groups at KCL. The event was organised in collaboration with the Cancer Research UK KHP Centre and the Quantitative Genomics Programme of the School of Cancer and Pharmaceutical Sciences at King's College London. |
| Year(s) Of Engagement Activity | 2017 |